Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Has results × Advanced Melanoma × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 387 Carcinoma, Non-Small-Cell Lung 320 Neoplasms 290 Prostatic Neoplasms 217 Leukemia, Myeloid, Acute 203 Multiple Myeloma 195 Neoplasm Metastasis 187 Melanoma 169 Leukemia 158 Lung Neoplasms 152 Lymphoma 146 Colorectal Neoplasms 136 Lymphoma, Non-Hodgkin 134 Pancreatic Neoplasms 133 Recurrence 130 Ovarian Neoplasms 127 Leukemia, Lymphocytic, Chronic, B-Cell 119 Precursor Cell Lymphoblastic Leukemia-Lymphoma 117 Carcinoma, Renal Cell 109 Myelodysplastic Syndromes 108 Lymphoma, Large B-Cell, Diffuse 97 Lymphoma, Follicular 96 Brain Neoplasms 91 Squamous Cell Carcinoma of Head and Neck 82 Glioblastoma 81 Head and Neck Neoplasms 79 Urinary Bladder Neoplasms 75 Carcinoma, Hepatocellular 73 Lymphoma, Mantle-Cell 63 Hodgkin Disease 62

Interventions

pembrolizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03407170 2020-07-15

KEYNOTE-161

Merck Sharp & Dohme LLC

Phase 2 Terminated

1 enrolled 3 charts

Advanced Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡